RANCHO CORDOVA, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced a comprehensive five-year, more than $200 million investment plan to expand and upgrade its U.S. development and manufacturing infrastructure across small molecules and peptides. The strategic initiative is a cornerstone of the company's broader global strategy to secure a resilient supply chain and support the unprecedented demands of its broad customer base..

加利福尼亚州兰乔科尔多瓦，2026年9月30日（环球新闻社）——SK pharmteco今日宣布一项为期五年、总额超过2亿美元的综合投资计划，旨在扩建和升级其在美国的小分子和肽类药物的开发与制造基础设施。这一战略举措是公司更广泛的全球战略的基石，旨在确保供应链的韧性，并满足其庞大客户群前所未有的需求。

This continues SK pharmteco’s global growth strategy, complementing the company's recent

此举延续了SK药明泰科（SK pharmteco）的全球增长战略，是对该公司近期

$6 million investment in its California facility

向其加州工厂投资600万美元

to boost peptide development, the

以促进肽类药物的开发，

opening of two advanced manufacturing facilities at its Ireland campus

在其爱尔兰园区开设两家先进制造设施

to scale up the site’s capability to deliver both large-scale commercial small molecules and ultra-high-potency active pharmaceutical ingredients (HPAPIs), and its

以扩大该基地大规模商业化小分子药物及超高活性药物成分（HPAPIs）的交付能力，并其

$260 million capacity expansion in South Korea

韩国2.6亿美元产能扩张项目

to expand global small molecule and peptide production.

以扩大全球小分子和肽类药物的生产。

As part of this new domestic plan, SK pharmteco will make targeted investments across key technology platforms, including:

作为这项新国内计划的一部分，SK pharmteco 将在关键技术平台上进行针对性投资，包括：

State-of-the-Art Development Labs:

顶尖开发实验室：

Launching new, fully operational development laboratories to accelerate early- through late-stage development for small molecules and peptides.

启动全新的、全面运作的研发实验室，以加速小分子和肽类药物从早期到后期的开发进程。

Advanced Peptide Purification:

高级肽纯化：

Expanding peptide manufacturing with new GMP kilo-scale capacity (scheduled to be operational in late 2026) alongside advanced liquid chromatography capabilities.

通过新增的GMP公斤级产能（计划于2026年底投产）以及先进的液相色谱技术，扩大肽类药物的生产能力。

Expanded & Upgraded Manufacturing:

扩展与升级的制造：

Constructing new manufacturing suites and modernizing existing GMP capacity to meet growing demand for small-molecule APIs.

建设新的生产设施并现代化改造现有的GMP产能，以满足对小分子原料药日益增长的需求。

Infrastructure & Sustainability:

基础设施与可持续发展：

Investing heavily in utility upgrades, logistics and digital infrastructures, and green technology to ensure sustainable, high-efficiency operations.

大力投资公用设施升级、物流与数字基础设施以及绿色技术，以确保可持续、高效益的运营。

The multi-year investment is projected to create 100 long-term, high-skilled jobs in the U.S., significantly strengthening domestic capabilities in active pharmaceutical ingredient (API), peptide, and advanced therapy supply.

这项多年期投资预计将在美国创造100个长期高技能就业岗位，显著增强国内在活性药物成分（API）、肽类以及先进疗法供应方面的能力。

'This commitment to our domestic operations marks a transformative milestone for SK pharmteco,' said Joerg Ahlgrimm, the company’s CEO. 'By expanding our domestic capabilities across small molecules and peptides, we are directly addressing unprecedented demand from our broad customer base. Combined with our focus on green technology and modern infrastructure, we are ensuring our customers have a highly reliable, sustainable, and cutting-edge partner from early-stage development through full commercialization.'.

SK pharmteco首席执行官Joerg Ahlgrimm表示：“这一对我们本土运营的承诺标志着SK pharmteco的一个变革性里程碑。通过扩大我们在小分子和肽类领域的本土能力，我们直接应对来自广泛客户群体的前所未有的需求。结合我们对绿色技术和现代基础设施的关注，我们确保客户从早期开发到全面商业化阶段都能拥有一个高度可靠、可持续且处于前沿的合作伙伴。”

About SK pharmteco

关于 SK pharmteco

SK pharmteco is a global contract development and manufacturing organization (CDMO) with production sites, research & development facilities, and analytical laboratories across the U.S., Europe, and South Korea. The company’s core capabilities center on small molecules, peptides, and viral vectors, providing the specialized expertise needed to bring complex therapies to market.

SK pharmteco 是一家全球合同研发与生产组织（CDMO），在美国、欧洲和韩国设有生产基地、研发设施和分析实验室。公司的核心能力聚焦于小分子、肽类和病毒载体，提供将复杂疗法推向市场所需的专业知识。

Through these pillars, SK pharmteco supports biopharmaceutical partners of all sizes with comprehensive development and manufacturing solutions worldwide. SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company for SK Group, South Korea’s second-largest conglomerate.   .

凭借这些核心优势，SK pharmteco 为全球各类规模的生物制药合作伙伴提供全面的开发与生产解决方案。SK pharmteco 是韩国第二大企业集团 SK 集团旗下的战略投资公司 SK Inc.（KRX: 034730）（简称“SK”）的子公司。

Contact:

联系方式：

Keith Bowermaster, APR, CCMP

基思·鲍尔马斯特，APR，CCMP

Communications Consultant

传播顾问

keith.bowermaster@skpt.com

keith.bowermaster@skpt.com